HLA class I transgenic mice: Development, utilisation and improvement

Expert Opinion on Biological Therapy

Volumn 5, Issue 7, 2005, Pages 919-938

  Pascolo, Steve ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Gene therapy; Messenger RNA; Vaccination

Indexed keywords

CARRIER PROTEIN; CD8 ANTIGEN; CHAPERONE; EPITOPE; HLA ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PROTEASOME; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN STRUCTURE; BIOCOMPATIBILITY; CANCER CELL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DNA RESPONSIVE ELEMENT; GENE EXPRESSION; GENE LOCUS; GENE THERAPY; GENETIC TRANSCRIPTION; HLA SYSTEM; HUMAN; IMMUNOSTIMULATION; NATURAL KILLER CELL; NONHUMAN; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; REVIEW; SPECIES COMPARISON; TRANSGENIC MOUSE; TRANSGENICS; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; EPITOPE MAPPING; GENE EXPRESSION REGULATION; GENES, MHC CLASS I; HUMANS; IMMUNODOMINANT EPITOPES; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; SPECIES SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

ANIMALIA; MUS MUSCULUS; VERTEBRATA;

EID: 22744444096     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.7.919     Document Type: Review

References (192)

1. BRINSTER RL, CHEN HY, TRUMBAUER M, SENEAR AW, WARREN R, PALMITER RD: Somatic expression of herpes thymidine kinase in mice following injection of a fusion gene into eggs. Cell (1981) 27:223-231.
2. PLOEGH HL, ORR HT, STROMINGER JL: Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell (1981) 24:287-299.
3. PERARNAU B, LEMONNIER F: Immunologically humanized transgenic mice. In: Weir's Handbook of Experimental Immunology Vol. 4. Herzenberg LA, Weir DM, Blacwell C (Eds), Blackwell Science, Inc., Malden, MD, USA (1997):146.
4. KELLEY J, WALTER L, TROWSDALE J: Comparative genomics of major histocompatibility complexes. Immunogenetics (2005) 56:683-695. This review presents briefly and clearly the homologies and differences between the MHC molecules from different species.
5. ZINKERNAGEL RM, DOHERTY PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 248:701-702.
6. PAULSSON KM: Evolutionary and functional perspectives of the major histocompatibility complex class I antigen-processing machinery. Cell Mol. Life Sci. (2004) 61:2446-2460.
7. NEWBERG MH, SMITH DH, HAERTEL SB, VINING DR, LACY E, ENGELHARD VH: Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J. Immunol. (1996) 156:2473-2480.
8. DAVIS DM, REYBURN HT, PAZMANY L, CHIU I, MANDELBOIM O, STROMINGER JL: Impaired spontaneous endocytosis of HLA-G. Eur. J. Immunol. (1997) 27:2714-2719.
9. VEGA MA, STROMINGER JL: Constitutive endocytosis of HLA class I antigens requires a specific portion of the intracytoplasmic tail that shares structural features with other endocytosed molecules. Proc. Natl. Acad. Sci. USA (1989) 86:2688-2692.
10. ZUNIGA MC, HOOD LE: Clonal variation in cell surface display of an H-2 protein lacking a cytoplasmic tail. J. Cell Biol. (1986) 102:1-10.
11. NAKAMURO K, TANIGAKI N, PRESSMAN D: Multiple common properties of human beta2-microglobulin and the common portion fragment derived from HL-A antigen molecules. Proc. Natl. Acad. Sci. USA (1973) 70:2863-2865.
12. PAULSSON K, WANG P: Chaperones and folding of MHC class I molecules in the endoplasmic reticulum. Biochim. Biophys. Acta (2003) 1641:1-12.
13. KOOPMANN JO, POST M, NEEFJES JJ, HAMMERLING GJ, MOMBURG F: Translocation of long peptides by transporters associated with antigen processing (TAP). Eur. J. Immunol. (1996) 26:1720-1728.
14. MOMBURG F, ROELSE J, HAMMERLING GJ, NEEFJES JJ: Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J. Exp. Med. (1994) 179:1613-1623.
15. FALK K, ROTZSCHKE O, STEVANOVIC S, JUNG G, RAMMENSEE HG: Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 351:290-296. Here the authors describe the fundamentals of the methods still used at present for MHC epitope prediction.
16. RAMMENSEE H, BACHMANN J, EMMERICH NP, BACHOR OA, STEVANOVIC S: SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 50:213-219.
17. SERWOLD T, GONZALEZ F, KIM J, JACOB R, SHASTRI N: ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature (2002) 419:480-483.
18. YORK IA, CHANG SC, SARIC T et al.: The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat. Immunol. (2002) 3:1177-1184.
19. BARNDEN MJ, PURCELL AW, GORMAN JJ, MCCLUSKEY J: Tapasin-mediated retention and optimization of peptide ligands during the assembly of class I molecules. J. Immunol. (2000) 165:322-330.
20. HORUZSKO A, ANTONIOU J, TOMLINSON P, PORTIK-DOBOS V, MELLOR AL: HLA-G functions as a restriction element and a transplantation antigen in mice. Int. Immunol. (1997) 9:645-653.
21. PACASOVA R, MARTINOZZI S, BOULOUIS HJ et al.: Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice. J. Immunol. (1999) 162:5190-5196.
22. SCHMIDT CM, GARRETT E, ORR HT: Cytotoxic T lymphocyte recognition of HLA-G in mice. Hum. Immunol. (1997) 55:127-139.
23. DAS P, ABRAHAM R, DAVID C: HLA transgenic mice as models of human autoimmune diseases. Rev. Immunogenet. (2000) 2:105-114.
24. BARBOSA JA, MENTZER SJ, MINOWADA G, STROMINGER JL, BURAKOFF SJ, BIRO PA: Recognition of HLA-A2 and -B7 antigens by cloned cytotoxic T lymphocytes after gene transfer into human and monkey, but not mouse, cells. Proc. Natl. Acad. Sci. USA (1984) 81:7549-7553.
25. MAZIARZ R, ALLEN H, STROMINGER JL, FLAVELL R, BIRO PA, BURAKOFF SJ: Recognition of interspecies hybrid class I histocompatibility antigens by antigen-specific cytolytic T lymphocytes. Proc. Natl. Acad. Sci. USA (1985) 82:6276-6280.
26. GOMARD E, BEGUE B, SODOYER S, MARYANSKIJL, JORDAN BR, LEVY JP: Murine cells expressing an HLA molecule are specifically lysed by HLA-restricted antiviral human T cells. Nature (1986) 319:153-154.
27. STREET MD, DOAN T, HERD KA, TINDLE RW: Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus Type 16 E7 protein. Immunology (2002) 106:526-536.
28. BRAUD VM, MCMICHAEL A, CERUNDOLO V: Differential processing of influenza nucleoprotein in human and mouse cells. Eur. J. Immunol. (1998) 28:625-635.
29. SESMA L, ALVAREZ I, MARCILLA M, PARADELA A, LOPEZ DE CASTRO JA: Species-specific differences in proteasomal processing and tapasin-mediated loading influence peptide presentation by HLA-B27 in murine cells. J. Biol. Chem. (2003) 278:46461-46472. The authors describe in the nicest and most complete way the only available study about systematic comparison between the repertoire of epitopes associated to a defined HLA class I molecule when it is expressed in human or in mouse cells. Moreover, through in vitro assays with purified proteasomes and complementation through gene transfections, the authors describe some of the steps in the antigen processing pathway that restrict antigen presentation in a species-specific manner.
30. KIEVITS F, IVANYI P, KRIMPENFORT P, BERNS A, PLOEGH HL: HLA-restricted recognition of viral antigens in HLA transgenic mice. Nature (1987) 329:447-449.
31. CHAMBERLAIN JW, NOLAN JA, GROMKOWSKI SH et al.: Cell surface expression and alloantigenic function of a human class I MHC heavy chain gene (HLA-B7) in transgenic mice. J. Immunol. (1988) 140:1285-1292.
32. ARNOLD B, HAMMERLING GJ: MHC class-I transgenic mice. Annu. Rev. Immunol. (1991) 9:297-322.
33. BERNHARD EJ, LE AX, YANNELLI JR et al.: The ability of cytotoxic T cells to recognize HLA-A2.1 or HLA-B7 antigens expressed on murine cells correlates with their epitope specificity. J. Immunol. (1987) 139:3614-3621.
34. BERNHARD EJ, LE AX, BARBOSA JA, LACY E, ENGELHARD VH: Cytotoxic T lymphocytes from HLA-A2 transgenic mice specific for HLA-A2 expressed on human cells. J. Exp. Med. (1988) 168:1157-1162.
35. DILL O, KIEVITS F, KOCH S, IVANYI P, HAMMERLING GJ: Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice. Proc. Natl. Acad. Sci. USA (1988) 85:5664-5668.
36. SCHONBACH C, NOKIHARA K, BANGHAM CR et al.: Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice. Virology (1996) 226:102-112.
37. MAN S, RIDGE JP, ENGELHARD VH: Diversity and dominance among TCR recognizing HLA-A2.1+ influenza matrix peptide in human MHC class I transgenic mice. J. Immunol. (1994) 153:4458-4467.
38. SETTE A, VITIELLO A, REHERMANN B et al.: The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. (1994) 153:5586-5592.
39. WENTWORTH P, VITIELLO A, SIDNEY J et al. Difference and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. (1996) 26:97-101.
40. EPSTEIN H, HARDY R, MAY JS, JOHNSON MH, HOLMES N: Expression and function of HLA-A2.1 in transgenic mice. Eur. J. Immunol. (1989) 19:1575-1583.
41. BARRA C, PERARNAU B, GERLINGER P et al.: Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice. J. Immunol. (1989) 143:3117-3124.
42. HAMMERLING GJ, HUNT T, DILL O, MORENO J: Cytotoxic T lymphocyte recognition of HLA-A2 antigens in normal and HLA-Cw3-transgenic mice. Eur. J. Immunol. (1989) 19:599-604.
43. KIEVITS F, BOERENKAMP WJ, LOKHORST W, IVANYI P: Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B27.2-, HLA-B27.5-, and HLA-Cw3-transgenic mice. A transgenic model for MHC xenoantigen recognition. J. Immunol. (1990) 144:4513-4519.
44. IRWIN MJ, HEATH WR, SHERMAN LA: Species-restricted interactions between CD8 and the alpha 3 domain of class I influence the magnitude of the xenogeneic response. J. Exp. Med. (1989) 170:1091-1101. This article highlights the species-specific recognition of MHC I molecules by murine and human CD8, and describes the involved regions on the MHC I molecules.
45. LAFACE DM, VESTBERG M, YANG Y et al.: Human CD8 transgene regulation of HLA recognition by murine T cells. J. Exp. Med. (1995) 182:1315-1325.
46. VITIELLO A, MARCHESINI D, FURZE J, SHERMAN LA, CHESNUT RW: Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. (1991) 173:1007-1015.
47. ALEXANDER J, OSEROFF C, SIDNEY J et al.: Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J. Immunol. (1997) 159:4753-4761.
48. BORENSTEIN SH, GRAHAM J, ZHANG XL, CHAMBERLAIN JW: CD8+ T cells are necessary for recognition of allelic, but not locus-mismatched or xeno-, HLA class I transplantation antigens. J. Immunol. (2000) 165:2341-2353.
49. KALINKE U, ARNOLD B, HAMMERLING GJ: Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 domain into HLA B27. Nature (1990) 348:642-644.
50. GOTOH M, TAKASU H, HARADA K, YAMAOKA T: Development of HLA-A2402/K(b) transgenic mice. Int. J. Cancer (2002) 100:565-570.
51. BARRA C, GOURNIER H, GARCIA Z et al.: Abrogation of H-2-restricted CTL responses and efficient recognition of HLA-A3 molecules in DBA/2 HLA/A24 responder mice. J. Immunol. (1993) 150:3681-3689. This study shows that when H-2-restricted CTL responses are abrogated, HLA-restricted CTL responses are strong and diverse. This is the fundamental study that triggered the development of third-generation HLA class I transgenic mice.
52. PASCOLO S, BERVAS N, URE JM, SMITH AG, LEMONNIER FA, PERARNAU B: HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. (1997) 185:2043-2051. This manuscript discloses the engineering and phenotype of the first third-generation HLA class I transgenic mouse.
53. URETA-VIDAL A, FIRAT H, PERARNAU B, LEMONNIER FA: Phenotypical and functional characterization of the CD8+ T cell repertoire of HLA-A2.1 transgenic, H-2KbnullDbnull double knockout mice. J. Immunol. (1999) 163:2555-2560.
54. CHEUK E, D'SOUZA C, HU N, LIU Y, LANG H, CHAMBERLAIN JW: Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes. J. Immunol. (2002) 169:5571-5580. Three different HLA class I alleles with or without a mouse alpha 3 domain are expressed in H-2 class I-deficient mice. The phenotype of the mice and their comparative capacitiy to mount an HLA-restricted immune response is reported.
55. BIX M, RAULET D: Functionally conformed free class I heavy chains exist on the surface of beta 2 microglobulin negative cells. J. Exp. Med. (1992) 176:829-834.
56. GLAS R, FRANKSSON L, OHLEN C et al.: Major histocompatibility complex class I-specific and -restricted killing of beta 2-microglobulin-deficient cells by CD8+ cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA (1992) 89:11381-11385.
57. FIRAT H, ZENNOU V, GARCIA-PONS F et al.: Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J. Gene Med. (2002) 4:38-45.
58. VYAS JM, SHAWAR SM, RODGERS JR, COOK RG, RICH RR: Biochemical specificity of H-2M3a. Stereospecificity and space-filling requirements at position 1 maintain N-formyl peptide binding. J. Immunol. (1992) 149:3605-3611.
59. FIRAT H, GARCIA-PONS F, TOURDOT S et al.: H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur. J. Immunol. (1999) 29:3112-3121.
60. FIRAT H, COCHET M, ROHRLICH PS et al.: Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int. Immunol. (2002) 14:925-934.
61. GALLEZ-HAWKINS G, VILLACRES MC, LI X, SANBORN MC, LOMELI NA, ZAIA JA: Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. J. Virol. (2003) 77:4457-4462.
62. RAMAGE JM, METHERING HAM R, MOSS R, SPENDLOVE I, REES R, DURRANT LG: Comparison of the immune response to a self antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice. Vaccine (2004) 22:1728-1731.
63. CHOI EM, CHEN JL, WOOLDRIDGE L et al.: High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J. Immunol. (2003) 171:5116-5123. Not only is a method to identify high-affinity T cells reported here, but also the fact that vaccinating with vectors that generate high amounts of antigen leads to the triggering of low-affinity CTLs.
64. DAFTARIAN P, ALI S, SHARAN R et al.: Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J. Immunol. (2003) 171:4028-4039.
65. PETER K, MEN Y, PANTALEO G, GANDER B, CORRADIN G: Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine (2001) 19:4121-4129.
66. ROHRLICH PS, CARDINAUD S, FIRAT H et al.: HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int. Immunol. (2003) 15:765-772.
67. BREBAN M, HACQUARD-BOUDER C, FALGARONE G: Animal models of HLA-B27-associated diseases. Curr. Mol. Med. (2004) 4:31-40.
68. KOLLNBERGER S, BIRD LA, RODDIS M et al.: HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-Iike receptors. J. Immunol. (2004) 173:1699-1710.
69. KUON W, LAUSTER R, BOTTCHER U et al.: Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. Arthritis Rheum. (1997) 40:945-954.
70. KUON W, KUHNE M, BUSCH DH et al.: Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy. J. Immunol. (2004) 173:4859-4866.
71. DREXLER I, STAI BC, KASTENMULLER W et al.: Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc. Natl. Acad. Sci. USA (2003) 100:217-222.
72. HUANG YH, TAO MH, HU CP, SYU WJ, WU JC: Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J. Gen. Virol. (2004) 85:3089-3098.
73. ROHRLICH PS, CARDINAUD S, LULE J et al.: Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells. Hum. Immunol. (2004) 65:514-522.
74. SEIFERT U, LIERMANN H, RACANELLI V et al.: Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. (2004) 114:250-259.
75. GRAFF-DUBOIS S, FAURE O, GROSS DA et al.: Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J. Immunol. (2002) 169:575-580.
76. PASCOLO S, SCHIRLE M, GUCKEL B et al.: A MAGE-A1 HLA-AA*0201 epitope identified by mass spectrometry. Cancer Res. (2001) 61:4072-4077.
77. VISSEREN MJ, VAN DER BURG SH, VAN DERVOORT EI et al.: Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int. J. Cancer (1997) 73:125-130.
78. CARMON L, EL SHAMI KM, PAZ A et al.: Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain. Int. J. Cancer (2000) 85:391-397.
79. PLONQUET A, GARCIA-PONS F, FERNANDEZ E et al.: Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J. Neuroimmunol. (2003) 142:93-100.
80. ALVES PM, FAURE O, GRAFF-DUBOIS S et al.: EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res. (2003) 63:8476-8480.
81. FAURE O, GRAFF-DUBOIS S, BRETAUDEAU L et al.: Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes. Int. J. Cancer (2004) 108:863-870.
82. JARAMILLO A, NARAYANAN K, CAMPBELL LG et al.: Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res. Treat. (2004) 88:29-41.
83. CARMON L, BOBILEV-PRIEL I, BRENNER B et al.: Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice. J. Clin. Invest. (2002) 110:453-462.
84. RAMAGE JM, METHERINGHAM R, CONN A et al.: Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2. Int. J. Cancer (2004) 110:245-250.
85. THEOBALD M, BIGGS J, HERNANDEZ J, LUSTGARTEN J, LABADIE C, SHERMAN LA: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. (1997) 185:833-841.
86. SCARDINO A, GROSS DA, ALVES P et al.: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J. Immunol. (2002) 168:5900-5906.
87. LUSTGARTEN J, THEOBALD M, LABADIE C et al.: Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. Hum. Immunol. (1997) 52:109-118.
88. STANISLAWSKI T, VOSS RH, LOTZ C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. (2001) 2:962-970.
89. GINHOUX F, DOUCET C, LEBOEUF M et al.: Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy. Mol. Ther. (2003) 8:274-283.
90. GINHOUX F, TURBANT S, GROSS DA et al.: HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. Mol. Ther. (2004) 10:279-289.
91. ALEXANDER J, OSEROFF C, DAHLBERG C et al.: A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J. Immunol. (2002) 168:6189-6198.
92. ALEXANDER J, OSEROFF C, SIDNEY J, SETTEA: Derivation of HLA-B*0702 transgenic mice: functional CTL repertoire and recognition of human B*0702-restricted CTL epitopes. Hum. Immunol. (2003) 64:211-223.
93. BAR-HAIM E, PAZ A, MACHLENKIN A et al.: MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br. J. Cancer (2004) 91:398-407.
94. ENGLER OB, SCHWENDENER RA, DAI WJ et al.: A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine (2004) 23:58-68.
95. FRANCINI G, SCARDINO A, KOSMATOPOULOS K et al.: High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. (2002) 169:4840-4849.
96. HERNANDEZ J, SCHOEDER K, BLONDELLE SE et al.: Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen. Eur. J. Immunol. (2004) 34:2331-2341.
97. MARTIN P, PARROCHE P, CHATEL L et al.: Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. J. Med. Virol. (2004) 74:397-405.
98. MCKINNEY DM, SKVORETZ R, LIVINGSTON BD et al.: Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. J. Immunol. (2004) 173:1941-1950.
99. OH S, TERABE M, PENDLETON CD et al.: Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res. (2004) 64:2610-2618.
100. BULLOCK TN, COLELLA TA, ENGELHARD VH: The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. (2000) 164:2354-2361.
101. MICONNET I, KOENIG S, SPEISER D et al.: CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. (2002) 168:1212-1218.
102. GARCIA F, SEPULVEDA P, LIEGEARD P et al.: Identification of HLA-A*0201-restricted cytotoxic T-cell epitopes of Trypanosoma cruzi TcP2beta protein in HLA-transgenic mice and patients. Microbes. Infect. (2003) 5:351-359.
103. GRITZAPIS AD, SOTIRIADOU NN, PAPAMICHAIL M, BAXEVANIS CN: Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors. Cancer Immunol. Immunother. (2004) 53:1027-1040.
104. HWANG YK, KIM NK, PARK JM et al.: HLA-A2 1 restricted peptides from the HBx antigen induce specific CTL responses in vitro and in vivo. Vaccine (2002) 20:3770-3777.
105. PLOTNICKY H, CYBLAT-CHANAL D, AUBRYJP et al.: The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice. Virology (2003) 309:320-329.
106. SNYDER JT, BELYAKOV IM, DZUTSEV A, LEMONNIER F, BERZOFSKY JA: Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. (2004) 78:7052-7060.
107. SUNDARAM R, LYNCH MP, RAWALE S et al.: Protective efficacy of multiepitope human leukocyte antigen-A*0201 restricted cytotoxic T-lymphocyte peptide construct against challenge with human T-cell lymphotropic virus type 1 Tax recombinant vaccinia virus. J. Acquir. Immune. Defic. Syndr. (2004) 37:1329-1339.
108. CORBET S, NIELSEN HV, VINNER L et al.: Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus Type 1-specific CTL epitopes. J. Gen. Virol. (2003) 84:2409-2421.
109. GROSS DA, GRAFF-DUBOIS S, OPOLON P et al.: High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J. Clin. Invest. (2004) 113:425-433.
110. LA ROSA C, WANG Z, BREWER JC et al.: Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood (2002) 100:3681-3689.
111. OKAZAKI T, PENDLETON CD, LEMONNIER F, BERZOFSKY JA: Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol. (2003) 171:2548-2555.
112. SHI TD, WU YZ, JIA ZC, ZHOU W, ZOU LY: Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice. World J. Gastroenterol. (2004) 10:1222-1226.
113. SUNDARAM R, SUN Y, WALKER CM, LEMONNIER FA, JACOBSON S, KAUMAYA PT: A novel multivalent human CTL peptide construct elicits robust cellular immune responses in HLA-A*0201 transgenic mice: implications for HTLV-1 vaccine design. Vaccine (2003) 21:2767-2781.
114. VERTUANI S, SETTE A, SIDNEY J et al.: Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J. Immunol. (2004) 172:3501-3508.
115. LOIRAT D, LEMONNIER FA, MICHEL ML: Multiepitopic HLA-A*0201- restricted immune response against hepatitis B surface antigen after DNA-based immunization. J. Immunol. (2000) 165:4748-4755.
116. WILSON CC, MCKINNEY D, ANDERS M et al.: Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J. Immunol. (2003) 171:5611-5623.
117. MATEO L, GARDNER J, CHEN Q et al.: An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J. Immunol. (1999) 163:4058-4063.
118. WOODBERRY T, GARDNER J, MATEO L et al.: Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes. J. Virol. (1999) 73:5320-5325.
119. BIVAS-BENITA M, VAN MEIJGAARDEN KE, FRANKEN KL et al.: Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine (2004) 22:1609-1615.
120. ROUARD H, KLONJKOWSKI B, MARQUET J et al.: Adenoviral transgene ubiquitination enhances mouse immunization and class I presentation by human dendritic cells. Hum. Gene Ther. (2003) 14:1319-1332.
121. TINE JA, FIRAT H, PAYNE A et al.: Enhanced multiepitope-based vaccines elicit CD8(+) cytotoxic T cells against both immunodominant and cryptic epitopes. Vaccine (2005) 23:1085-1091.
122. DADAGLIO G, MOREL S, BAUCHE C et al.: Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. Int. Immunol. (2003) 15:1423-1430.
123. ANDRE F, CHAPUT N, SCHARTZ NE et al.: Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. (2004) 172:2126-2136.
124. ISAGULIANTS MG, ZUBER B, BOBERG A et al.: Reverse transcriptase-based DNA vaccines against drug-resistant HIV-1 tested in a mouse model. Vaccine (2004) 22:1810-1819.
125. MATSUI Y: Increased density of class I major histocompatibility complex antigens and decreased density of T-cell differentiation antigens in the early stages of T-cell activation. Hum. Immunol. (1987) 18:123-133.
126. NARAYANAN K, JARAMILLO A, BENSHOFF ND et al.: Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J. Natl. Cancer Inst. (2004) 96:1388-1396.
127. PANCHOLI P, PERKUS M, TRICOCHE N, LIU Q, PRINCE AM: DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. (2003) 77:382-390.
128. SINGH RA, BARRY MA: Generation of multivalent genome-wide T cell responses in HLA-A*0201 transgenic mice by an HIV-1 expression library immunization (ELI) vaccine. Res. Initiat. Treat. Action (2003) 8:17-19.
129. SINGH RA, BARRY MA: Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J. Immunol. (2004) 173:4387-4393.
130. CHARO J, SUNDBACK M, GELUK A, OTTENHOFF T, KIESSLING R: DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. Hum. Gene Ther. (2001) 12:1797-1804.
131. RACANELLI V, BEHRENS SE, ALIBERTI J, REHERMANN B: Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity. (2004) 20:47-58.
132. ABRAHAM JD, HIMOUDI N, KIEN F et al.: Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine (2004) 22:3917-3928.
133. CASSETTI MC, MCELHINEY SP, SHAHABI V et al.: Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 22:520-527.
134. DIDIERLAURENT A, RAMIREZ JC, GHERARDI M et al.: Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine (2004) 22:3395-3403.
135. PALMOWSKI MJ, LOPES L, IKEDA Y, SALIO M, CERUNDOLO V, COLLINS MK: Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. (2004) 172:1582-1587.
136. WANG Z, LA ROSA C, MEKHOUBAD S et al.: Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood (2004) 104:847-856.
137. WEDEMEYER H, GAGNETEN S, DAVIS A, BARTENSCHLAGER R, FEINSTONE S, REHERMANN B: Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. Gastroenterology (2001) 121:1158-1166.
138. QIAO M, MURATA K, DAVIS AR, JEONG SH, LIANG TJ: Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology (2003) 37:52-59.
139. SCARDINO A, CORREALE P, FIRAT H et al.: In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse. Br. J. Cancer (2003) 89:199-205.
140. CHAPUT N, SCHARTZ NE, ANDRE F et al.: Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. (2004) 172:2137-2146.
141. MARASKOVSKY E, SJOLANDER S, DRANE DP et al.: NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin. Cancer Res. (2004) 10:2879-2890.
142. LIAO YP, WANG CC, BUTTERFIELD LH et al.: Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J. Immunol. (2004) 173:2462-2469.
143. ABDEL-MOTAL UM, FRIEDLINE R, POLIGONE B, POGUE-CALEY RR, FRELINGER JA, TISCH R: Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. Clin. Immunol. (2001) 101:51-58.
144. GALLEZ-HAWKINS G, LI X, FRANCK AE et al.: DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice. Vaccine (2004) 23:819-826.
145. BRINSTER C, CHEN M, BOUCREUX D et al.: Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. (2002) 83:369-381.
146. CARRALOT JP, PROBST J, HOERR I et al.: Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines. Cell. Mol. Life Sci. (2004) 61:2418-2424.
147. HOERR I, OBST R, RAMMENSEE HG, JUNG G: In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. (2000) 30:1-7.
148. PASCOLO S: Messenger RNA-based vaccines. Expert Opin. Biol. Ther. (2004) 4:1285-1294.
149. HIMOUDI N, ABRAHAM JD, FOURNILLIER A et al.: Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J. Virol. (2002) 76:12735-12746.
150. SATOI J, MURATA K, LECHMANN M et al.: Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J. Virol. (2001) 75:12121-12127.
151. GOLDSTEIN SA, MESCHER MF: Carbohydrate moieties of major histocompatibility complex class I alloantigens are not required for their recognition by T lymphocytes. J. Exp. Med. (1985) 162:1381-1386.
152. VILLANUEVA MS, BECKERS CJ, PAMER EG: Infection with Listeria monocytogenes impairs sialic acid addition to host cell glycoproteins. J. Exp. Med. (1994) 180:2137-2145.
153. BOOG CJ, NEEFJES JJ, BOES J, PLOEGH HL, MELIEF CJ: Specific immune responses restored by alteration in carbohydrate chains of surface molecules on antigen-presenting cells. Eur. J. Immunol. (1989) 19:537-542.
154. NEEFJES JJ, DE BRUIJN ML, BOOG CJ et al.: N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response. J. Exp. Med. (1990) 171:583-588.
155. NOSSNER E, PARHAM P: Species-specific differences in chaperone interaction of human and mouse major histocompatibility complex class I molecules. J. Exp. Med. (1995) 181:327-337.
156. SCHMIDT W, FESTENSTEIN H, WARD PJ, SANDERSON AR: Interspecies exchange of beta 2-microglobulin and associated MHC and differentiation antigens. Immunogenetics (1981) 13:483-491.
157. MARTIEN VS, WOOLSEY A, RICKARDT PG et al.: Increase in positive selection of CD8+ T cells in TAP1-mutant mice by human beta 2-microglobulin transgene. J. Exp. Med. (1995) 181:787-792.
158. FERRIER P, KAHN-PERLES B, LAYET C et al.: Serological and structural analysis of HLA class I molecules: beta 2-microglobulin interacts with the two external domains of the HLA class I heavy chain. Ann. Inst. Pasteur Immunol. (1987) 138:19-35.
159. PERARNAU B, SIEGRIST CA, GILLET A, VINCENT C, KIMURA S, LEMONNIER FA: Beta 2-microglobulin restriction of antigen presentation. Nature (1990) 346:751-754.
160. GROETTRUP M, SOZA A, KUCKELKORN U, KLOETZEL PM: Peptide antigen production by the proteasome: complexity provides efficiency. Immunol. Today (1996) 17:429-435.
161. ROCK KL, GRAMM C, ROTHSTEIN L et al.: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 78:761-771.
162. MONACO JJ, NANDI D: The genetics of proteasomes and antigen processing. Annu. Rev. Genet. (1995) 29:729-754.
163. FRUH K, GOSSEN M, WANG K, BUJARD H, PETERSON PA, YANG Y: Displacement of housekeeping proteasome subunits by MHC-encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. EMBO J. (1994) 13:3236-3244.
164. TOES RE, NUSSBAUM AK, DEGERMANN S et al.: Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. (2001) 194:1-12.
165. SPIES T, BRESNAHAN M, BAHRAM S et al.: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature (1990) 348:744-747.
166. SPIES T, DEMARS R: Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature (1991) 351:323-324.
167. SCHUMACHER TN, KANTESARIA DV, HEEMELS MT et al.: Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J. Exp. Med. (1994) 179:533-540.
168. MOMBURG F, ROELSE J, HOWARD JC, BUTCHER GW, HAMMERLING GJ, NEEFJES JJ: Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature (1994) 367:648-651.
169. OBST R, ARMANDOLA EA, NIJENHUIS M, MOMBURG F, HAMMERLING GJ: TAP polymorphism does not influence transport of peptide variants in mice and humans. Eur. J. Immunol. (1995) 25:2170-2176.
170. QUADRI SA, SINGAL DP: Peptide transport in human lymphoblastoid and tumor cells: effect of transporter associated with antigen presentation (TAP) polymorphism. Immunol. Lett. (1998) 61:25-31.
171. LIVINGSTONEAM, POWIS SJ, GUNTHER E, CRAMER DV, HOWARD JC, BUTCHER GW: Cim: an MHC class II-linked allelism affecting the antigenicity of a classical class I molecule for T lymphocytes. Immunogenetics (1991) 34:157-163.
172. TING JP, BALDWIN AS: Regulation of MHC gene expression. Curr. Opin. Immunol. (1993) 5:8-16.
173. HOBART M, RAMASSAR V, GOES N, URMSON J, HALLORAN PF: IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. J. Immunol. (1997) 158:4260-4269.
174. GOBIN SJ, PEIJNENBURG A, KEIJSERS V, VAN DEN ELSEN PJ: Site alpha is crucial for two routes of IFN gamma-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity (1997) 6:601-611.
175. SCHONEICH J, LEE JL, MANSKY P, SHEFFERY M, YANG SY: The pentanucleotide ATTGG, the 'inverted CCAAT,' is an essential element for HLA class I gene transcription. J. Immunol. (1997) 158:4788-4796.
176. MATZINGER P: Tolerance, danger, and the extended family. Annu. Rev. Immunol. (1994) 12:991-1045.
177. MATZINGER P: The danger model: a renewed sense of self. Science (2002) 296:301-305.
178. ALEXOPOULOU L, HOLT AC, MEDZHITOV R, FLAVELL RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 413:732-738.
179. HEMMI H, KAISHO T, TAKEUCHI O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. (2002) 3:196-200.
180. MIZEL SB, WEST AP, HANTGAN RR: Identification of a sequence in human Toll-like receptor 5 required for the binding of Gram-negative flagellin. J. Biol. Chem. (2003) 278:23624-23629.
181. SCHEEL B, BRAEDEL S, PROBST J et al.: Immunostimulating capacities of stabilized RNA molecules. Eur. J. Immunol. (2004) 34:537-547.
182. YANG RB, MARK MR, GRAY A et al.: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature (1998) 395:284-288.
183. REHLI M: Of mice and men: species variations of Toll-like receptor expression. Trends Immunol. (2002) 23:375-378. This paper indicates that care must be taken when generalising to the human situation the results obtained in mice with vaccine formulations 'adjuvanted' with danger signals.
184. SCHEEL B, TEUFEL R, PROBST J et al.: Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur. J. Immunol. (2005) 35(5):1557-1566.
185. VOLLMER J, WEERATNA R, PAYETTE P et al.: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. (2004) 34:251-262.
186. TERME M, TOMASELLO E, MARUYAMA K et al.: IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J. Immunol. (2004) 172:5957-5966.
187. LUSTGARTEN J, DOMINGUEZ AL, CUADROS C: The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity. Eur. J. Immunol. (2004) 34:752-761.
188. ZHOUH, LUO Y, MIZUTANI M et al.: A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J. Clin. Invest. (2004) 113:1792-1798.
189. LOIRAT D, MANCINI-BOURGINE M, ABASTADO JP, MICHEL ML: HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection. Int. Immunol. (2003) 15:1125-1136.
190. TUSSEY LG, ROWLAND-JONES S, ZHENG TS et al.: Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity (1995) 3:65-77.
191. LACEY SF, VILLACRES MC, LA ROSA C et al.: Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum. Immunol. (2003) 64:440-452.
192. PAJOT A, MICHEL ML, FAZILLEAU N et al.: A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. (2004) 34:3060-3069.